ASX:BD1

BARD1 Life Sciences Competitors

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume801,545 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

BARD1 Life Sciences (ASX:BD1) Vs. BUX, IME, CRL, CTE, DVL, and EPGNY

Should you be buying BD1 stock or one of its competitors? Companies in the industry of "diagnostics & research" are considered alternatives and competitors to BARD1 Life Sciences, including (BUX) (BUX), 12144 (IME), Charles River Laboratories International (CRL), Cryosite (CTE), dorsaVi (DVL), and Epigenomics (EPGNY).

(BUX) (CNSX:BUX) and BARD1 Life Sciences (ASX:BD1) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, risk, earnings, valuation and institutional ownership.

Earnings & Valuation

This table compares (BUX) and BARD1 Life Sciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
(BUX)N/AN/AN/AN/AN/A
BARD1 Life Sciences$612,251.000.00$-6,644,706.43A($0.08)N/A

(BUX) has higher earnings, but lower revenue than BARD1 Life Sciences.

Profitability

This table compares (BUX) and BARD1 Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
(BUX)N/AN/AN/A
BARD1 Life SciencesN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and target prices for (BUX) and BARD1 Life Sciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
(BUX)0000N/A
BARD1 Life Sciences0000N/A

Summary

BARD1 Life Sciences beats (BUX) on 1 of the 1 factors compared between the two stocks.

BARD1 Life Sciences (ASX:BD1) and 12144 (CNSX:IME) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for BARD1 Life Sciences and 12144, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BARD1 Life Sciences0000N/A
121440000N/A

Earnings and Valuation

This table compares BARD1 Life Sciences and 12144's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BARD1 Life Sciences$612,251.000.00C$-6,644,706.43A($0.08)N/A
12144N/AN/AN/AN/AN/A

12144 has lower revenue, but higher earnings than BARD1 Life Sciences.

Profitability

This table compares BARD1 Life Sciences and 12144's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BARD1 Life SciencesN/AN/AN/A
12144N/AN/AN/A

Summary

BARD1 Life Sciences beats 12144 on 1 of the 1 factors compared between the two stocks.

Charles River Laboratories International (CNSX:CRL) and BARD1 Life Sciences (ASX:BD1) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation.

Earnings and Valuation

This table compares Charles River Laboratories International and BARD1 Life Sciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Charles River Laboratories InternationalN/AN/AN/AN/AN/A
BARD1 Life Sciences$612,251.000.00$-6,644,706.43A($0.08)N/A

Charles River Laboratories International has higher earnings, but lower revenue than BARD1 Life Sciences.

Profitability

This table compares Charles River Laboratories International and BARD1 Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Charles River Laboratories InternationalN/AN/AN/A
BARD1 Life SciencesN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings for Charles River Laboratories International and BARD1 Life Sciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Charles River Laboratories International0000N/A
BARD1 Life Sciences0000N/A

Summary

BARD1 Life Sciences beats Charles River Laboratories International on 1 of the 1 factors compared between the two stocks.

BARD1 Life Sciences (ASX:BD1) and Cryosite (ASX:CTE) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, dividends, analyst recommendations and risk.

Profitability

This table compares BARD1 Life Sciences and Cryosite's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BARD1 Life SciencesN/AN/AN/A
CryositeN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for BARD1 Life Sciences and Cryosite, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BARD1 Life Sciences0000N/A
Cryosite0000N/A

Valuation and Earnings

This table compares BARD1 Life Sciences and Cryosite's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BARD1 Life Sciences$612,251.000.00$-6,644,706.43A($0.08)N/A
Cryosite$9.71 million0.00$515,455.60A$0.01N/A

Cryosite has higher revenue and earnings than BARD1 Life Sciences.

Summary

Cryosite beats BARD1 Life Sciences on 3 of the 3 factors compared between the two stocks.

dorsaVi (ASX:DVL) and BARD1 Life Sciences (ASX:BD1) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.

Valuation and Earnings

This table compares dorsaVi and BARD1 Life Sciences' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
dorsaVi$1.65 million0.00$-3,158,396.93A($0.01)N/A
BARD1 Life Sciences$612,251.000.00$-6,644,706.43A($0.08)N/A

dorsaVi has higher revenue and earnings than BARD1 Life Sciences.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for dorsaVi and BARD1 Life Sciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
dorsaVi0000N/A
BARD1 Life Sciences0000N/A

Profitability

This table compares dorsaVi and BARD1 Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
dorsaViN/AN/AN/A
BARD1 Life SciencesN/AN/AN/A

Summary

dorsaVi beats BARD1 Life Sciences on 3 of the 3 factors compared between the two stocks.

BARD1 Life Sciences (ASX:BD1) and Epigenomics (OTCMKTS:EPGNY) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings for BARD1 Life Sciences and Epigenomics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BARD1 Life Sciences0000N/A
Epigenomics0000N/A

Profitability

This table compares BARD1 Life Sciences and Epigenomics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BARD1 Life SciencesN/AN/AN/A
EpigenomicsN/AN/AN/A

Earnings and Valuation

This table compares BARD1 Life Sciences and Epigenomics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BARD1 Life Sciences$612,251.000.00$-6,644,706.43A($0.08)N/A
EpigenomicsN/AN/AN/AN/AN/A

Epigenomics has lower revenue, but higher earnings than BARD1 Life Sciences.

Summary

BARD1 Life Sciences beats Epigenomics on 1 of the 1 factors compared between the two stocks.


BARD1 Life Sciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
BUX
(BUX)
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
IME
12144
0.5N/AN/AC$0.00N/A0.00High Trading Volume
Gap Down
CRL
Charles River Laboratories International
0.5N/AN/A$0.00N/A0.00Gap Up
CTE
Cryosite
0.6N/AN/A$0.00$9.71 million0.00High Trading Volume
Gap Up
DVL
dorsaVi
0.5N/AN/A$0.00$1.65 million0.00High Trading Volume
Gap Up
Epigenomics logo
EPGNY
Epigenomics
0.6$13.77flat$0.00N/A0.00Increase in Short Interest
ETAH
Eternity Healthcare
0.6$0.00flat$0.00N/A0.00
GSS
Genetic Signatures
0.0N/AN/A$0.00$29.13 million0.00High Trading Volume
GTG
Genetic Technologies
0.0N/AN/A$0.00$25,714.000.00High Trading Volume
IBX
Imagion Biosystems
0.6N/AN/A$0.00$2.70 million0.00High Trading Volume
Gap Up
IDX
Integral Diagnostics
0.8N/AN/A$0.00$314.82 million0.00High Trading Volume
Gap Up
LSH
Lifespot Health
0.5N/AN/A$0.00$22,127.000.00High Trading Volume
Gap Up
MEDD
Medical Imaging
0.4$0.01flat$0.00N/A0.00News Coverage
Gap Down
OSL
OncoSil Medical
0.5N/AN/A$0.00$2.22 million0.00High Trading Volume
Gap Up
Parallax Health Sciences logo
PRLX
Parallax Health Sciences
0.5$0.01flat$0.00N/A0.00Gap Up
RHY
Rhythm Biosciences
0.0N/AN/A$0.00$1.21 million0.00High Trading Volume
Sartorius Aktiengesellschaft logo
SRT3
Sartorius Aktiengesellschaft
0.6$465.90flat$0.00N/A0.00High Trading Volume
SENS
Senseonics
0.0N/AN/A$0.00N/A0.00High Trading Volume
SENS
Senseonics
0.0N/AN/A$0.00N/A0.00High Trading Volume
Siemens Healthineers logo
SMMNY
Siemens Healthineers
0.5$27.98flat$0.00N/A0.00Decrease in Short Interest
SIL
Smiles Inclusive
0.4N/AN/A$0.00$36.48 million0.00High Trading Volume
Gap Up
VHT
Volpara Health Technologies
0.5N/AN/A$0.00$15.22 million0.00High Trading Volume
Gap Up
OBJ
Wellfully Limited (OBJ.AX)
0.0N/AN/A$0.00$1.48 million0.00High Trading Volume
WUXIF
WuXi AppTec
1.0$19.88flat$0.00N/A0.00
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.